You are here:
Safe and effective human papillomarivus vaccines offer protection against 70% of all cervical cancer cases.
GAVI supports inactivated polio vaccine as part of routine immunisation programmes.
GAVI funds JE catch up campaigns. Countries self-finance the vaccine for routine immunisation.
GAVI supports the Measles Initiative and a second round of measles vaccination jabs.
GAVI-funded rubella vaccines are now combined for easy delivery with measles vaccines in a single measles-rubella shot.
MenAfriVac vaccine could prevent 150,000 deaths by 2015 in Africa's "meningitis belt".
By 2015 GAVI aims to have supported the vaccination of 270 million children with pentavalent vaccine.
GAVI plans to support the rollout of pneumococcal vaccines in over 40 countries by 2015.
Ten GAVI-eligible countries have added rotavirus vaccine to their immunisation programmes.
GAVI provides yellow fever support for routine immunisation, campaigns in high-risk countries and emergency stockpiles in case of outbreaks.
There is no limit to the number of vaccines that a country can apply for in a single application round, but only one vaccine per country will be funded in a single round and applicants must propose an introduction date within two years of the actual application round.
Countries can also request support for the partial introduction of a vaccine or a phased rollout. In addition, GAVI funds auto-disable syringes and safety boxes, sent to successful country applicants together with the vaccines.
All countries must co-finance GAVI-supported vaccines, except for measles second dose and preventative campaigns for yellow fever and meningitis A; in no case will GAVI support replace government funds already allocated for the purchase of vaccines.
Initially, the NVS programme provided five-year support grants with the expectation that countries would cover continued vaccination cost after GAVI’s support ended. This assumed that GAVI’s business model would drive down the price of vaccines within five years to the point where poor countries could afford to pay themselves. When it became apparent that vaccine prices were not dropping quickly enough, GAVI revised its support timelines to be based on country planning cycles.
Today, countries can only request NVS support for the duration of comprehensive Multi-Year Plans for immunization – this ensurs that vaccine rollouts are aligned with the national health and budgetary planning process.
Approximately six million future deaths averted from hepatitis B, Haemophilus influenzae type B, measles, pertussis, pneumococcal disease, polio, rotavirus diarrhoea and yellow fever since GAVI's launch in 2000.
© GAVI Alliance 2014
modal window here